Tag: Eisai

Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy

Eisai Co., Ltd. and MSD agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.

Japanese company Eisai expands its capacity in China

Eisai Co. Ltd., announced today that its Chinese subsidiary, Eisai China Inc. has completed construction of a new oral solid dose production facility